pioglitazone has been researched along with Kahler Disease in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated whether treatment with pioglitazone (PGZ), rosiglitazone (RGZ) or 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) inhibited tumor cell growth in five human multiple myeloma cell lines (LP-1, U-266, RPMI-8226-S, OPM-2 and IM-9) and human bone marrow myeloma cells expressing PPAR-gamma protein." | 3.72 | Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma. ( Bängeroth, K; Elstner, E; Eucker, J; Heider, U; Jakob, C; Krebbel, H; Possinger, K; Sezer, O; Zang, C; Zavrski, I, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tentolouris, A | 1 |
| Ntanasis-Stathopoulos, I | 1 |
| Eleftheriadou, I | 1 |
| Malandrakis, P | 1 |
| Tzeravini, E | 1 |
| Gavriatopoulou, M | 1 |
| Aouali, N | 1 |
| Palissot, V | 1 |
| El-Khoury, V | 1 |
| Moussay, E | 1 |
| Janji, B | 1 |
| Pierson, S | 1 |
| Brons, NH | 1 |
| Kellner, L | 1 |
| Bosseler, M | 1 |
| Van Moer, K | 1 |
| Berchem, G | 1 |
| Eucker, J | 1 |
| Bängeroth, K | 1 |
| Zavrski, I | 1 |
| Krebbel, H | 1 |
| Zang, C | 1 |
| Heider, U | 1 |
| Jakob, C | 1 |
| Elstner, E | 1 |
| Possinger, K | 1 |
| Sezer, O | 1 |
| Burton, JD | 1 |
| Castillo, ME | 1 |
| Goldenberg, DM | 1 |
| Blumenthal, RD | 1 |
1 review available for pioglitazone and Kahler Disease
| Article | Year |
|---|---|
Diabetes mellitus and multiple myeloma; common features of two distinct entities.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Multiple Myeloma; Pioglitazone | 2022 |
3 other studies available for pioglitazone and Kahler Disease
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells.
Topics: Acetylation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspa | 2009 |
Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma.
Topics: Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Humans; Ligands; Multiple Myelom | 2004 |
Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma; Caspase Inhibitors; Caspases; Cel | 2007 |